Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency

The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percuta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular medicine reports 2014-08, Vol.10 (2), p.593-598
Hauptverfasser: CHEN, BIN, LIU, DA-LIE, PAN, WEN-YAN, YANG, XIAO-HUI, SHOU, JIA-BAO, WU, JU-HUA, MAO, QING-LONG, WANG, JIA
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 598
container_issue 2
container_start_page 593
container_title Molecular medicine reports
container_volume 10
creator CHEN, BIN
LIU, DA-LIE
PAN, WEN-YAN
YANG, XIAO-HUI
SHOU, JIA-BAO
WU, JU-HUA
MAO, QING-LONG
WANG, JIA
description The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.
doi_str_mv 10.3892/mmr.2014.2251
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4094769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A427301033</galeid><sourcerecordid>A427301033</sourcerecordid><originalsourceid>FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</originalsourceid><addsrcrecordid>eNptkk2LFDEQhhtR3HX16FUCHvSwPea7O5eFZfELFry455BOV3YyppM26VmYf2-GGUdXJIcUlafeShVv07wmeMV6RT9MU15RTPiKUkGeNOekU6RlGPOnx5gq1Z01L0rZYCwFFep5c0Z5L_qOqvNmc1cAJYeCn1MwcVn7FH0ENMO8-BEukUFLCqEN_gegDLamU0YU-bj2g6_xJYK4NtFCQUs2sYyQJxPQCME_QN4hcM5bD9HuXjbPnAkFXh3vi-bu08fvN1_a22-fv95c37ZW9HhpBXN0UGrAUom-J5Q4rHopOqGssM5yJ8WAh1FKQzkXTA3WYauUk5SNo8KEXTRXB915O0wwWoj1Y0HP2U8m73QyXj9-iX6t79OD5ljxTqoq8P4okNPPLZRFT75YCHU_kLZFE8GEpIp0oqJv_0E3aZtjHU8TxSiXknTkD3VvAmgfXap97V5UX3PaMUwwY5Va_YeqZ4TJ2xTB-Zp_VNAeCmxOpWRwpxkJ1ntz6GoOvTeH3puj8m_-XsyJ_u2GCrw7AGU2cfRjKiemKrUEt5i2WCjGfgEGp8HA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932466171</pqid></control><display><type>article</type><title>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>CHEN, BIN ; LIU, DA-LIE ; PAN, WEN-YAN ; YANG, XIAO-HUI ; SHOU, JIA-BAO ; WU, JU-HUA ; MAO, QING-LONG ; WANG, JIA</creator><creatorcontrib>CHEN, BIN ; LIU, DA-LIE ; PAN, WEN-YAN ; YANG, XIAO-HUI ; SHOU, JIA-BAO ; WU, JU-HUA ; MAO, QING-LONG ; WANG, JIA</creatorcontrib><description>The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.</description><identifier>ISSN: 1791-2997</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2014.2251</identifier><identifier>PMID: 24858729</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Administration, Cutaneous ; Analgesics ; Analysis ; Animals ; Blood levels ; Capillaries ; Claudin-4 - metabolism ; Control ; Dimethyl sulfoxide ; Dimethyl Sulfoxide - pharmacology ; Dislocation ; Drug delivery ; Drug delivery systems ; Drugs ; Edema ; Efficiency ; Enhancers ; Health aspects ; Immunohistochemistry ; Inflammation ; LacZ gene ; Ligands ; lipolanthionine peptide ; Mice ; Mice, Inbred BALB C ; Pathogens ; Peptides - pharmacology ; Permeability ; Permeability - drug effects ; Physiological aspects ; Plasmids ; Plasmids - genetics ; Plasmids - metabolism ; Polymerase chain reaction ; Proteins ; Retinoic acid ; Side effects ; Signal transduction ; Skin ; Skin - drug effects ; Skin - pathology ; Stratum corneum ; toll-like receptor 2 ; Toll-Like Receptor 2 - antagonists &amp; inhibitors ; Toll-Like Receptor 2 - metabolism ; Toll-like receptors ; transdermal delivery system ; Transdermal medication ; Tretinoin ; Tretinoin - pharmacology ; Zonula occludens-1 protein ; Zonula Occludens-1 Protein - metabolism</subject><ispartof>Molecular medicine reports, 2014-08, Vol.10 (2), p.593-598</ispartof><rights>Copyright © 2014, Spandidos Publications</rights><rights>COPYRIGHT 2014 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2014</rights><rights>Copyright © 2014, Spandidos Publications 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</citedby><cites>FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,5570,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24858729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHEN, BIN</creatorcontrib><creatorcontrib>LIU, DA-LIE</creatorcontrib><creatorcontrib>PAN, WEN-YAN</creatorcontrib><creatorcontrib>YANG, XIAO-HUI</creatorcontrib><creatorcontrib>SHOU, JIA-BAO</creatorcontrib><creatorcontrib>WU, JU-HUA</creatorcontrib><creatorcontrib>MAO, QING-LONG</creatorcontrib><creatorcontrib>WANG, JIA</creatorcontrib><title>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</title><title>Molecular medicine reports</title><addtitle>Mol Med Rep</addtitle><description>The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.</description><subject>Administration, Cutaneous</subject><subject>Analgesics</subject><subject>Analysis</subject><subject>Animals</subject><subject>Blood levels</subject><subject>Capillaries</subject><subject>Claudin-4 - metabolism</subject><subject>Control</subject><subject>Dimethyl sulfoxide</subject><subject>Dimethyl Sulfoxide - pharmacology</subject><subject>Dislocation</subject><subject>Drug delivery</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Edema</subject><subject>Efficiency</subject><subject>Enhancers</subject><subject>Health aspects</subject><subject>Immunohistochemistry</subject><subject>Inflammation</subject><subject>LacZ gene</subject><subject>Ligands</subject><subject>lipolanthionine peptide</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Pathogens</subject><subject>Peptides - pharmacology</subject><subject>Permeability</subject><subject>Permeability - drug effects</subject><subject>Physiological aspects</subject><subject>Plasmids</subject><subject>Plasmids - genetics</subject><subject>Plasmids - metabolism</subject><subject>Polymerase chain reaction</subject><subject>Proteins</subject><subject>Retinoic acid</subject><subject>Side effects</subject><subject>Signal transduction</subject><subject>Skin</subject><subject>Skin - drug effects</subject><subject>Skin - pathology</subject><subject>Stratum corneum</subject><subject>toll-like receptor 2</subject><subject>Toll-Like Receptor 2 - antagonists &amp; inhibitors</subject><subject>Toll-Like Receptor 2 - metabolism</subject><subject>Toll-like receptors</subject><subject>transdermal delivery system</subject><subject>Transdermal medication</subject><subject>Tretinoin</subject><subject>Tretinoin - pharmacology</subject><subject>Zonula occludens-1 protein</subject><subject>Zonula Occludens-1 Protein - metabolism</subject><issn>1791-2997</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkk2LFDEQhhtR3HX16FUCHvSwPea7O5eFZfELFry455BOV3YyppM26VmYf2-GGUdXJIcUlafeShVv07wmeMV6RT9MU15RTPiKUkGeNOekU6RlGPOnx5gq1Z01L0rZYCwFFep5c0Z5L_qOqvNmc1cAJYeCn1MwcVn7FH0ENMO8-BEukUFLCqEN_gegDLamU0YU-bj2g6_xJYK4NtFCQUs2sYyQJxPQCME_QN4hcM5bD9HuXjbPnAkFXh3vi-bu08fvN1_a22-fv95c37ZW9HhpBXN0UGrAUom-J5Q4rHopOqGssM5yJ8WAh1FKQzkXTA3WYauUk5SNo8KEXTRXB915O0wwWoj1Y0HP2U8m73QyXj9-iX6t79OD5ljxTqoq8P4okNPPLZRFT75YCHU_kLZFE8GEpIp0oqJv_0E3aZtjHU8TxSiXknTkD3VvAmgfXap97V5UX3PaMUwwY5Va_YeqZ4TJ2xTB-Zp_VNAeCmxOpWRwpxkJ1ntz6GoOvTeH3puj8m_-XsyJ_u2GCrw7AGU2cfRjKiemKrUEt5i2WCjGfgEGp8HA</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>CHEN, BIN</creator><creator>LIU, DA-LIE</creator><creator>PAN, WEN-YAN</creator><creator>YANG, XIAO-HUI</creator><creator>SHOU, JIA-BAO</creator><creator>WU, JU-HUA</creator><creator>MAO, QING-LONG</creator><creator>WANG, JIA</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140801</creationdate><title>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</title><author>CHEN, BIN ; LIU, DA-LIE ; PAN, WEN-YAN ; YANG, XIAO-HUI ; SHOU, JIA-BAO ; WU, JU-HUA ; MAO, QING-LONG ; WANG, JIA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c580t-53f2b99b069588121f09865759c5cfc4f65b0bd66a244539bcf0c99f623dd9013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Cutaneous</topic><topic>Analgesics</topic><topic>Analysis</topic><topic>Animals</topic><topic>Blood levels</topic><topic>Capillaries</topic><topic>Claudin-4 - metabolism</topic><topic>Control</topic><topic>Dimethyl sulfoxide</topic><topic>Dimethyl Sulfoxide - pharmacology</topic><topic>Dislocation</topic><topic>Drug delivery</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Edema</topic><topic>Efficiency</topic><topic>Enhancers</topic><topic>Health aspects</topic><topic>Immunohistochemistry</topic><topic>Inflammation</topic><topic>LacZ gene</topic><topic>Ligands</topic><topic>lipolanthionine peptide</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Pathogens</topic><topic>Peptides - pharmacology</topic><topic>Permeability</topic><topic>Permeability - drug effects</topic><topic>Physiological aspects</topic><topic>Plasmids</topic><topic>Plasmids - genetics</topic><topic>Plasmids - metabolism</topic><topic>Polymerase chain reaction</topic><topic>Proteins</topic><topic>Retinoic acid</topic><topic>Side effects</topic><topic>Signal transduction</topic><topic>Skin</topic><topic>Skin - drug effects</topic><topic>Skin - pathology</topic><topic>Stratum corneum</topic><topic>toll-like receptor 2</topic><topic>Toll-Like Receptor 2 - antagonists &amp; inhibitors</topic><topic>Toll-Like Receptor 2 - metabolism</topic><topic>Toll-like receptors</topic><topic>transdermal delivery system</topic><topic>Transdermal medication</topic><topic>Tretinoin</topic><topic>Tretinoin - pharmacology</topic><topic>Zonula occludens-1 protein</topic><topic>Zonula Occludens-1 Protein - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHEN, BIN</creatorcontrib><creatorcontrib>LIU, DA-LIE</creatorcontrib><creatorcontrib>PAN, WEN-YAN</creatorcontrib><creatorcontrib>YANG, XIAO-HUI</creatorcontrib><creatorcontrib>SHOU, JIA-BAO</creatorcontrib><creatorcontrib>WU, JU-HUA</creatorcontrib><creatorcontrib>MAO, QING-LONG</creatorcontrib><creatorcontrib>WANG, JIA</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHEN, BIN</au><au>LIU, DA-LIE</au><au>PAN, WEN-YAN</au><au>YANG, XIAO-HUI</au><au>SHOU, JIA-BAO</au><au>WU, JU-HUA</au><au>MAO, QING-LONG</au><au>WANG, JIA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency</atitle><jtitle>Molecular medicine reports</jtitle><addtitle>Mol Med Rep</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>10</volume><issue>2</issue><spage>593</spage><epage>598</epage><pages>593-598</pages><issn>1791-2997</issn><eissn>1791-3004</eissn><abstract>The transdermal delivery system (TDS) is able to obtain a systemic therapeutic effect by administration through the skin, which has low side effects and is able to maintain a sustained blood concentration. However, due to the barrier presented by the stratum corneum, numerous drugs have poor percutaneous permeability. Therefore, the improvement of skin permeability is key to TDS. The main method of promoting transdermal absorption is through the usage of penetration enhancers. Dimethyl sulfoxide (DMSO) is a commonly used penetration enhancer, which has anti-inflammatory analgesic effects and is able to penetrate the skin. Retinoic acid (RA) and lipolanthionine peptide (LP) may also benefit the permeation efficiency of TDS. Therefore, the present study examined the function of DMSO, RA and LP as penetration enhancers in TDS. Firstly, the optimum concentration of DMSO was confirmed by detecting the expression of the LacZ gene in vitro. Secondly, different combinations of LP, RA and DMSO were applied to mouse skin to analyze the penetration enhancer combination with the greatest efficacy. All the animals were divided into five groups: The RA + LP + DMSO + pORF-LacZ group, the RA + DMSO + pORF-LacZ group, the LP + DMSO + pORF-LacZ group, the DMSO + pORF-LacZ group and the control group. Skin was soaked in combinations of LP, RA and DMSO for seven days and then the pORF-LacZ plasmids were daubed onto the skin once daily three days. On the 11th day, all the animals were sacrificed by cervical dislocation and the skin and blood samples were collected. The blood samples were used to detect the expression of the LacZ gene by quantitative polymerase chain reaction and the skin samples were used to detect the expression of claudin-4 and zonula occluden-1 (ZO-1) proteins by immunohistochemistry and western blot analysis. The results demonstrated that the combination of LP, RA and DMSO exhibited the greatest transdermal delivery efficiency, which verified that RA and LP were able to increase the penetration effects. Following treatment with LP, the symptoms of dermal edema were relieved and the capillaries contracted, which suggested that LP was a safe and effective penetration enhancer able to reduce the side-effects caused by DMSO. The present study provides a guideline for the synthesis of novel penetration enhancers.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>24858729</pmid><doi>10.3892/mmr.2014.2251</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1791-2997
ispartof Molecular medicine reports, 2014-08, Vol.10 (2), p.593-598
issn 1791-2997
1791-3004
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4094769
source Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Administration, Cutaneous
Analgesics
Analysis
Animals
Blood levels
Capillaries
Claudin-4 - metabolism
Control
Dimethyl sulfoxide
Dimethyl Sulfoxide - pharmacology
Dislocation
Drug delivery
Drug delivery systems
Drugs
Edema
Efficiency
Enhancers
Health aspects
Immunohistochemistry
Inflammation
LacZ gene
Ligands
lipolanthionine peptide
Mice
Mice, Inbred BALB C
Pathogens
Peptides - pharmacology
Permeability
Permeability - drug effects
Physiological aspects
Plasmids
Plasmids - genetics
Plasmids - metabolism
Polymerase chain reaction
Proteins
Retinoic acid
Side effects
Signal transduction
Skin
Skin - drug effects
Skin - pathology
Stratum corneum
toll-like receptor 2
Toll-Like Receptor 2 - antagonists & inhibitors
Toll-Like Receptor 2 - metabolism
Toll-like receptors
transdermal delivery system
Transdermal medication
Tretinoin
Tretinoin - pharmacology
Zonula occludens-1 protein
Zonula Occludens-1 Protein - metabolism
title Use of lipolanthionine peptide, a toll-like receptor 2 inhibitor, enhances transdermal delivery efficiency
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A59%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20lipolanthionine%20peptide,%20a%20toll-like%20receptor%202%20inhibitor,%20enhances%20transdermal%20delivery%20efficiency&rft.jtitle=Molecular%20medicine%20reports&rft.au=CHEN,%20BIN&rft.date=2014-08-01&rft.volume=10&rft.issue=2&rft.spage=593&rft.epage=598&rft.pages=593-598&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2014.2251&rft_dat=%3Cgale_pubme%3EA427301033%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932466171&rft_id=info:pmid/24858729&rft_galeid=A427301033&rfr_iscdi=true